Paget's disease of the vulva Treatment

How Treatment Approaches Are Chosen for This Rare Condition

When someone receives a diagnosis of Paget's disease of the vulva, the treatment journey begins with understanding that this is not a one-size-fits-all condition. This rare intraepithelial adenocarcinoma—a type of cancer that starts in the layer of cells forming the skin surface—represents only 1-2% of all vulvar cancers, which means that medical teams must draw on specialized knowledge rather than standardized protocols1. The primary goal of treatment is to remove or destroy the abnormal cells while preserving as much normal tissue and function as possible. However, because Paget's disease often extends beyond what can be seen with the naked eye, achieving this balance presents significant challenges.

Treatment decisions depend heavily on whether the disease is confined to the surface layer of skin (non-invasive) or has penetrated deeper into the underlying tissue (invasive). Healthcare providers also consider the extent of the affected area, the patient's overall health and age, and whether there are any associated cancers in nearby organs such as the bladder, rectum, or uterus. Between 7% and 40% of cases may be linked to an underlying cancer, which significantly influences the treatment approach2. The disease is most commonly diagnosed in postmenopausal women, often after symptoms like itching, burning, and redness have been present for two years or more3.

Because Paget's disease of the vulva tends to recur even after treatment, the approach must also include a long-term monitoring plan. Many patients face multiple treatment procedures over the course of 10 to 20 years, which can impact quality of life and emotional well-being1. Therefore, treatment planning involves not just removing visible disease, but also preparing for the possibility of future recurrences and managing the functional and psychological consequences of repeated interventions.

Standard Treatment: Surgery as the Primary Approach

Surgery remains the most commonly used treatment for Paget's disease of the vulva, despite ongoing challenges with recurrence. The standard surgical approach involves wide local excision, which means removing the visible lesion along with a margin of surrounding healthy tissue—typically 2 to 3 centimeters beyond the edges that can be seen1. The rationale behind removing such a wide margin is that Paget cells often spread in ways that are not visible to the eye, creating irregular borders that extend far beyond the red, scaly patches that appear on the skin3.

The type of surgery performed depends on how extensive the disease is. For smaller, localized areas, a wide local excision may be sufficient. In more extensive cases, surgeons may need to perform a hemivulvectomy (removal of half of the vulva) or even a complete bilateral vulvectomy (removal of most or all of the vulva)4. After such extensive tissue removal, reconstruction is often necessary, requiring collaboration between gynecologic oncology surgeons and plastic surgeons to restore both function and appearance1.

One specialized surgical technique that may be used is Mohs micrographic surgery. This approach involves removing the tissue in very thin layers, examining each layer under a microscope immediately to check for abnormal cells, and continuing until no cancer cells are detected at the margins. This method can be particularly useful when the disease affects areas where preserving tissue is especially important, such as near the clitoris or inner labia, because it allows for more precise removal while sparing healthy tissue5.

A significant challenge with surgical treatment is that even when the margins appear clear under initial examination, recurrence rates remain high. Studies show that surgical margins are positive—meaning abnormal cells are still present at the edges of the removed tissue—in 60% to 70% of cases1. Even when margins are negative, recurrence rates can reach 33% to 60%1. This high recurrence rate means that many women undergo multiple surgical procedures over many years, which can lead to progressive loss of vulvar tissue, scarring, pain, and significant impact on sexual function and quality of life.

For patients with invasive disease—where cancer cells have penetrated beyond the surface layer into deeper tissue—additional procedures may be needed. If the pathology report after surgery indicates invasion, doctors may recommend inguinal lymphadenectomy, which involves removing lymph nodes from the groin area to check whether cancer has spread1. However, this procedure is not routinely performed for non-invasive Paget's disease.

Recovery from vulvar surgery varies depending on the extent of the procedure. Patients typically experience pain, swelling, and difficulty with urination and bowel movements in the weeks following surgery. Sexual activity is usually restricted for several weeks. When extensive tissue has been removed and reconstruction performed, healing may take several months. Physical complications can include chronic pain, scarring, narrowing of the vaginal opening, and altered sensation. The emotional impact of repeated surgeries and changes to genital anatomy can also be profound, affecting self-image, intimacy, and relationships.

Non-Surgical Treatment Options: Topical Therapies and Other Approaches

Given the challenges and complications associated with repeated surgeries, medical researchers have explored non-surgical alternatives. These treatments aim to destroy abnormal cells without removing tissue, potentially reducing the physical and emotional burden on patients. However, it's important to note that these approaches are generally considered alternatives or complements to surgery rather than standard first-line treatments.

One of the most studied non-surgical treatments is imiquimod cream. Imiquimod is an immune response modifier—it works by stimulating the body's own immune system to recognize and attack abnormal cells. Patients apply this cream directly to the affected area, usually several times per week for several months. The largest study examining imiquimod for vulvar Paget's disease, which included 51 patients, reported a 43% response rate1. This means that less than half of patients experienced significant improvement with this treatment. Imiquimod can be used for both surface-level disease and cases with minimal invasion into deeper tissue. Common side effects include redness, irritation, pain, skin breakdown, and ulceration at the application site1.

Another topical medication that has been tried is fluorouracil (also known as 5-FU), a chemotherapy agent that can be applied directly to the skin. Like imiquimod, fluorouracil works by interfering with the growth of abnormal cells. However, it also commonly causes significant skin irritation, pain, and breakdown of the treated tissue1. Some treatment protocols have also explored topical bleomycin, another chemotherapy drug, though experience with this approach is limited.

Photodynamic therapy represents another non-invasive option. This treatment involves applying a light-sensitive medication to the affected area, which is then absorbed by the abnormal cells. After a waiting period, the area is exposed to a specific wavelength of light, which activates the medication and destroys the cells that absorbed it. Because the medication is preferentially absorbed by abnormal cells, this approach can be more selective than simply removing tissue. However, photodynamic therapy can cause significant pain, skin breakdown, and ulceration during the healing process1.

Laser therapy, particularly using carbon dioxide lasers, offers another way to destroy abnormal tissue without traditional surgical removal. The laser essentially vaporizes the affected tissue layer by layer. While this approach can be effective, it shares the same fundamental problem as other treatments: determining exactly where the disease ends is difficult because Paget cells often extend beyond visible margins. Side effects include pain, scarring, and skin discoloration1.

Radiation therapy may be used in specific situations, particularly for elderly patients or those with medical conditions that make surgery too risky. Radiation can also be combined with surgery to treat areas where disease has recurred or where surgical removal would be especially difficult5. The radiation is typically delivered externally, with multiple treatment sessions over several weeks. Side effects can include skin irritation, pain, scarring, and long-term changes to the treated tissue.

For all these non-surgical approaches, it's crucial to understand that evidence supporting their effectiveness is limited. Most published information comes from small case series or individual case reports rather than large, well-designed clinical trials. A systematic review specifically looking for randomized controlled trials—the gold standard for medical evidence—found no such studies comparing different treatments for Paget's disease of the vulva6. This lack of high-quality evidence makes it difficult to definitively say which treatment approach is best, and treatment decisions often rely on the experience of individual physicians and the specific circumstances of each patient.

Treatment in Clinical Trials: Exploring New Possibilities

Because Paget's disease of the vulva is so rare and current treatments have significant limitations, researchers continue to search for better approaches through clinical trials. However, the rarity of this condition makes conducting large studies extremely challenging. Most research institutions see only a handful of new cases each year, which means that gathering enough patients to test new treatments takes considerable time and coordination across multiple medical centers.

Clinical trials for Paget's disease of the vulva typically fall into several categories. Some trials focus on refining existing treatments—for example, testing different doses or schedules of imiquimod application to see if effectiveness can be improved while reducing side effects. Other trials explore whether combining treatments might work better than single approaches alone. For instance, researchers might study whether using topical therapy before surgery can reduce the extent of surgery needed, or whether applying topical treatment after surgery might reduce recurrence rates.

Given that Paget's disease involves abnormal growth of specific types of cells, researchers are also interested in whether targeted therapies developed for other cancers might be effective. These could include drugs that interfere with specific molecular pathways involved in cell growth and survival. However, because Paget's disease of the vulva is so rare, most of these drugs would first be tested in more common cancers, and only later might researchers explore their potential for this condition.

One area of ongoing investigation involves better understanding the biology of Paget's disease itself. Research has explored the role of various proteins and genetic changes in these cells, such as the tumor suppressor protein p537. By understanding what drives the growth of these abnormal cells at a molecular level, scientists hope to identify new targets for therapy. However, translating these biological insights into actual treatments that patients can use remains a significant challenge.

Another research direction involves improving diagnostic techniques to better identify the true extent of disease before and during treatment. Some studies have explored whether special imaging techniques or more sophisticated ways of examining tissue samples could help surgeons more accurately determine where Paget cells are located, potentially leading to more complete removal with fewer recurrences.

Clinical trials may be conducted at various phases. Phase I trials primarily focus on safety—determining whether a new treatment is safe enough to give to patients and at what dose. Phase II trials examine whether the treatment actually works against the disease and continue to monitor safety in a larger group of patients. Phase III trials compare the new treatment directly against the current standard treatment to determine if it's better, worse, or about the same.

For patients interested in participating in clinical trials, eligibility typically depends on several factors including the stage and extent of disease, whether they've had previous treatments, overall health status, and sometimes the specific characteristics of the Paget cells as determined by laboratory testing. Because Paget's disease of the vulva is rare, patients may need to travel to specialized centers to participate in trials, which might be located in major cities in the United States, Europe, or other regions with large cancer research institutions.

Follow-Up and Long-Term Monitoring

Regardless of which initial treatment approach is used, long-term follow-up is absolutely essential for patients with Paget's disease of the vulva. The high recurrence rates mean that regular monitoring can detect new or returning disease early, when it may be easier to treat. Patients typically need lifelong surveillance, with examinations becoming more frequent in the years immediately after treatment and potentially continuing every few months for many years8.

Follow-up visits usually include a thorough visual examination of the entire vulvar area, as well as palpation (feeling) for any changes in the tissue. Because Paget's disease can be multifocal—meaning it can develop in more than one area—the entire vulvar region must be carefully assessed, not just the site of previous treatment. Any suspicious areas may be biopsied to determine whether they represent recurrent disease.

Patients should be taught to perform self-examinations between medical appointments and to report any new symptoms promptly. Warning signs that should prompt immediate contact with healthcare providers include new areas of redness, itching that doesn't respond to simple moisturizers, skin thickening, bleeding, or the development of lumps or bumps.

The prognosis for patients with non-invasive Paget's disease of the vulva is generally favorable, with five-year survival rates approaching 90%1. However, this relatively good survival rate must be balanced against the reality that most patients will experience recurrences requiring repeated treatments. When the disease is invasive or associated with underlying cancers, the prognosis becomes less favorable and depends heavily on the specific type and stage of cancer present.

Most common treatment methods

• Surgical approaches
  • Wide local excision with 2-3 cm margins beyond visible disease
  • Hemivulvectomy or complete vulvectomy for extensive disease
  • Mohs micrographic surgery for tissue-sparing removal in sensitive areas
  • Vulvar and perineal reconstruction after extensive tissue removal
  • Inguinal lymphadenectomy if invasion is detected on pathology
• Topical therapies
  • Imiquimod cream applied several times weekly for months, with 43% response rate
  • Fluorouracil (5-FU) topical chemotherapy
  • Topical bleomycin in selected cases
  • Corticosteroid creams for symptom management
• Ablative treatments
  • Carbon dioxide laser therapy to vaporize abnormal tissue
  • Photodynamic therapy using light-activated medications
• Radiation therapy
  • External beam radiation for patients unable to undergo surgery
  • Radiation combined with surgery for recurrent disease
  • Radiation to reduce recurrence risk in selected cases